Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice

Bernardo Ortega, Jason M. Dey, Allison R. Gardella, Jacob Proano & Deanna Vaneerde

Department of Biology, The College at Brockport, State University of New York, Brockport, New York

Keywords
EGFR, FGF23, Klotho, magnesium deficiency, phosphate, PTH.

Correspondence
Bernardo Ortega, Department of Biology, The College at Brockport, State University of New York, 350 New Campus Drive, Brockport, NY 14420-2973.
Tel: 1 585 3955190
Fax: 1 585 3952741
E-mail: bortega@brockport.edu

Funding Information
No funding information provided.

Received: 22 December 2016; Accepted: 30 January 2017
doi: 10.14814/phy2.13176

Physiol Rep, 5 (5), 2017, e13176,
doi: 10.14814/phy2.13176

Abstract
Monoclonal antibody therapies targeting the EGF receptor (EGFR) frequently result in hypomagnesemia in human patients. In contrast, EGFR tyrosine kinase inhibitors do not affect Mg2+ balance in patients and only have a mild effect on Mg2+ homeostasis in rodents at elevated doses. EGFR has also been shown to affect phosphate (P) transport in rat and rabbit proximal convoluted tubules (PCT), but evidence from studies targeting EGFR and looking at P excretion in whole animals is still missing. Thus, the role of EGF in regulating reabsorption of Mg2+ and P in the kidney remains controversial. Here, we inject mice with the anti-EGFR monoclonal antibody ME-1 for 2 weeks and observe a significant increase in serum P and mild hypomagnesemia, but no changes in P or Mg2+ excretion. In contrast, a single injection of ME-1 resulted in hyperphosphatemia and a significant reduction in P excretion 2 days after treatment, while no changes in serum Mg2+ or Mg2+ excretion were observed. Dietary Mg2+ deprivation is known to trigger a rapid Mg2+ conservation response in addition to hyperphosphatemia and hyperphosphaturia. Interestingly, one dose of ME-1 did not significantly modify the response of mice to 2 days of Mg2+ deprivation. These data show that EGFR plays a significant role in regulating P reabsorption in the kidney PCT, but suggest only a minor role in long-term regulation of Mg2+ transport in the distal convoluted tubule.

Introduction
The kidney plays a critical role in maintaining Mg2+ and phosphate (P) homeostasis. Within hours of Mg2+ deprivation, animals maintained on a Mg2+-deficient diet present hypomagnesemia despite development of a rapid Mg2+ conservation response. These animals also show disturbed P, Ca2+, K+, and Na+ balance (MacManus and Heaton 1969; Rude et al. 2003; Ortega et al. 2015). The discovery that a mutation in the epidermal growth factor (EGF) gene caused a rare autosomal recessive disorder known as isolated recessive renal hypomagnesemia (IRRH) pointed at EGF as a significant factor in the regulation of Mg2+ homeostasis (Groenestege et al. 2007). Although Mg2+ reabsorption in the kidneys takes place at the proximal convoluted tube and thick ascending limb (TAL), regulated Mg2+ reabsorption is mostly concentrated at the distal convoluted tubule (DCT) via the apical Mg2+ channel TRPM6. In the kidney, the EGF receptor (EGFR) is expressed in the TAL and DCT (Groenestege et al. 2007; Ferre et al. 2011). When expressed in HEK293 cells, the activity of TRPM6 is stimulated by addition of EGF, via activation of endogenous EGFRs (Groenestege et al. 2007). Interestingly, prolonged treatment (2 months) with cetuximab, a monoclonal antibody that targets and inhibits human EGFR, occasionally induces profound hypomagnesemia and urinary salt wasting in patients undergoing colorectal cancer treatment (Schrag et al. 2005; Groenestege et al. 2007; Izzedine et al. 2010).
Anti-EGF-based therapies used in the treatment of non-small-cell lung cancer include EGFR tyrosine kinase inhibitors such as erlotinib or gefitinib (Loriot et al. 2008), that do not result in hypomagnesemia (Altundag et al. 2005). In contrast to cetuximab, these chemical inhibitors are not species-specific, allowing for experimental studies to be performed in non-human models. A recent study showed that after treating mice with erlotinib for 16 days, only a mild decrease in serum Mg²⁺ was detected, while the fractional excretion of Mg²⁺ remained unchanged (Dimke et al. 2010). This study used a high dose of erlotinib (92 mg/kg/day, intraperitoneal) that resulted in serum levels of erlotinib up to 10 times greater than those found in human patients. The authors argue that monoclonal-based therapies achieve greater bioavailability of the drug than chemical inhibitors, explaining why only a large dose of erlotinib can affect serum Mg²⁺.

Another study performed in rats reported a mild decrease in plasma Mg²⁺ after 3 weeks of erlotinib treatment (10 mg/kg/day, oral), with further reduction in plasma Mg²⁺ taking place as treatment continued for up to 9 weeks (Mak et al. 2015). Thus, chemical EGFR inhibitors appear to have only moderate effects in Mg²⁺ metabolism, even when used at high doses.

Most of the filtered P⁰ is reabsorbed in the proximal kidney tubules via a transcellular process that involves P₁ entry via apical Na-P₁ cotransporters, and P₂ exit via unidentified transporters. The role of EGF in regulating P₁ reabsorption in the proximal convoluted tubule remains controversial. In cultured LLC-PK1 renal epithelial cells and isolated perfused rabbit PCT, EGF caused stimulation of Na-P₁ cotransport (Goodyer et al. 1988; Quigley et al. 1995). In contrast, EGF has been shown to inhibit NaPi, co-transport activity in brush border membrane vesicles isolated from rats treated with EGF (Arar et al. 1999). The authors of this study detected a decrease in NaPi-2 protein abundance, but there was no change in NaPi-2 mRNA abundance. To our knowledge, no animal study has investigated the effect on P₁ excretion of either administering recombinant EGF or blocking EGFR.

This study investigates the role of EGF in regulating P₁ and Mg²⁺ metabolism using the rat anti-mouse EGFR monoclonal antibody ME-1. ME-1 has been successfully used to block EGFR in mice, where it induces skin inflammation and triggers important histologic changes after 1 week of treatment (Surguladze et al. 2009). We first investigate the ability of long-term (2 weeks) or short-term (2 days) ME-1 administration to induce hypomagnesemia or hyperphosphatemia, and then we administer a single dose of ME-1 to Mg²⁺-deprived or control mice in order to investigate the involvement of EGFR in the Mg²⁺ conservation response triggered by dietary Mg²⁺ deprivation.

Materials and Methods

Animal studies

Ten-week-old C57BL/6j male mice (Harlan, Madison, WI) were maintained in a temperature-controlled room under a 12 h light-dark cycle. For the 2-week ME-1 treatment, mice were maintained on standard diet (18% Protein Teklad Rodent Diet 2018, Envigo, East Millstone, NJ USA) and tap water ad libitum. ME-1 (9.9 mg/mL in saline) was kindly provided by ImClone (Eli Lilly). Control rat IgG (Equitech-Bio Inc, Kerrville, TX) was depropargenated using a Detoxi-Gel™ kit (Thermo Fisher Scientific, Rockford, IL). Six doses of ME-1 or control rat IgG (40 mg/kg) were administered intraperitoneally at regular intervals for a period of 2 weeks. On the last day of the experiment, mice were individually housed in metabolic cages, food and water consumption were measured and 24 h urine was collected under mineral oil to prevent evaporation. At the end of the experiment, mice were anesthetized using Avertin™ (tribromoethanol, Thermo Fisher Scientific) and approximately 800 μL of blood was collected using cardiac puncture. To produce serum, blood was allowed to clot at room temperature for 30 min and centrifuged for 20 min at 3500 g. For the experiment studying the effect of ME-1 on the Mg²⁺-saving response triggered by Mg²⁺ deprivation, deionized drinking water and experimental diets were provided ad libitum. Both Mg²⁺-deficient experimental diet (0.003% Mg; Teklad TD.93106, Harlan Teklad, Madison, WI) and Mg²⁺-control diet (0.2% Mg; Teklad TD.130120, Harlan Teklad) contained 0.45% w/w phosphorus, 0.6% w/w Ca²⁺ and 2200 IU/kg vitamin D. Prior to the experiment, all mice were maintained in Mg²⁺-control diet for 6 days. Next, mice were injected with one dose of ME-1 (40 mg/kg) or control IgG and allocated to their respective experimental groups and diets (Mg²⁺-deficient or Mg²⁺-control). Next day, mice were housed in metabolic cages, food and water consumption were measured, and 24 h urine was collected. At the end of the experiment, mice were anesthetized and serum was obtained as before. All experimental procedures were approved by the institutional animal care and use committee of The College at Brockport, State University of New York.

Analytical procedures

All chemicals were purchased from Thermo Fisher Scientific unless otherwise stated. Total serum bilirubin was determined using a sulfanilic acid colorimetric assay (Fossati et al. 1989). A working solution was prepared containing 0.7 mol/L HCl, 2.5 mmol/L sodium nitrate, 10 mmol/L sulfanilic acid, 1 mol/L citric acid, 0.5 mol/L...
caffeine, 3 mol/L urea and 0.5 g/L tyloxapol. In a multi-well plate, 10 μL of serum was added to 150 μL of working solution and incubated for 5 min. Absorbance of samples was read at 590 nm (Synergy H1, BioTek, Ventura, CA) and the concentration in samples was calculated from a standard curve prepared using known amounts of bilirubin. Bilirubin standards were produced by dilution of a bilirubin stock solution in 5% BSA/phosphate-buffered saline (PBS). A bilirubin stock solution was prepared by diluting 14.6 mg of bilirubin in 1 mL of 0.1 N NaOH, and then diluting 20 μL of the resulting solution in 980 μL of 5% BSA/PBS. Colorimetric assays for determination of Mg$^{2+}$ (using calmagite) and inorganic phosphorus (using malachite green-phosphomolybdate) in serum and urine, and Ca$^{2+}$ in urine (using O-cre-solphthalain complexone) have been described before (Ortega et al. 2015). Na$^+$ and K$^+$ in both serum and urine were measured using a flame photometer according to the manufacturer’s instructions (Jenway PFP7, Jenway Limited, Gransmore Green, Dunmow, Essex, UK). Total Ca$^{2+}$ in serum was analyzed using flame photometry following precipitation as calcium oxalate according to the manufacturer’s instructions as described before (Ortega et al. 2015). Statistical analysis was performed using SPSS statistical software (IBM Corporation, Armonk, NY). Results from different experimental groups were compared using an independent sample t-test or an ANOVA followed by Fisher’s LSD test. Statistical significance was assumed at $P < 0.05$.

Results

Changes in the integument associated with ME-1 administration

Patients receiving EGFR antibody therapy often experience skin rashes in areas rich in pilosebaceous units. SCID mice treated with ME-1 display inflammatory skin changes that result in a characteristic wavy hair pattern (Surguladze et al. 2009). Consistently, C57BL/6J mice in our study showed a similar pattern from the first week of ME-1 administration (Fig. 1), indicating that treatment was effective in inhibiting EGFR.

Effects of long-term ME-1 administration on mouse electrolyte balance

After 2 weeks of ME-1 administration, mice were placed in metabolic cages and 24-h urine was collected. Mice were then sacrificed and serum was obtained. No significant changes in body weight or water and food intake were observed between experimental and control groups (data not shown). EGFR-targeted anti-tumor therapies have been shown to occasionally disrupt bilirubin metabolism and produce hepatotoxicity (Kubitz et al. 2004; Loriot et al. 2008). In our study, there were no differences in serum bilirubin between ME-1-treated and control mice (ME-1: $2.62 \pm 0.28 \mu$mol/L; control: $3.62 \pm 0.27 \mu$mol/L, mean ± SE; n = 7, P < 0.05), showing that at the dose used, ME-1 induced no adverse effects. As shown in Table 1, mild hypomagnesemia resulted from 2 weeks of ME-1 administration. Furthermore, serum P$_i$ in ME-1-treated animals increased to a level bordering hyperphosphatemia. Other electrolytes, including Ca$^{2+}$, Na$^+$, and K$^+$, remained unchanged. No differences were observed in urine output or electrolyte excretion between treated and untreated animals.

Involvement of EGFR in maintaining electrolyte balance during short-term Mg$^{2+}$ deprivation

We have previously shown that short-term Mg$^{2+}$ deprivation elicits a rapid Mg$^{2+}$ saving response that results in reduced Mg$^{2+}$ excretion, hypomagnesemia, increased serum K$^+$ concentration, hypocalemia and hyperphosphatemia (Ortega et al. 2015). Mice also decreased their urine output, and develop hypocaliuria and hyperphosphaturia. Interestingly, except hypomagnesemia, all serum perturbations are compensated after 1 week of Mg$^{2+}$ deprivation, while excretion of Mg$^{2+}$ and Ca$^{2+}$ remains low, and that of P$_i$ stays elevated (Ortega et al. 2015). Given that long-term administration of ME-1 appeared to have a modest effect on metabolism of Mg$^{2+}$ and other
ME-1, and then switched to Mg$^{2+}$-deficient diet or maintained in control diet for a day. Next, mice were placed in metabolic cages with the same diet as before for additional 24 h. As expected, Mg$^{2+}$-deprivation decreased urine output and Mg$^{2+}$ excretion, in addition to inducing a profound hypomagnesemia (Fig. 2). However, treatment with ME-1 did not affect any of these parameters, indicating that EGFR is not likely involved in Mg$^{2+}$ conservation during the first 2 days of Mg$^{2+}$ deprivation. As shown in Figure 3A–B, administration of ME-1 did not modify Ca$^{2+}$ excretion or serum Ca$^{2+}$ concentration during normal or reduced Mg$^{2+}$ intake. Interestingly, ME-1 strongly reduced P$_i$ excretion (Fig. 3C) and increased serum P$_i$ (Fig. 3D) in mice fed control diet. As expected, Mg$^{2+}$ deprivation decreased Mg$^{2+}$ excretion (Fig. 2A) and increased serum P$_i$ (Fig. 3D). However, ME-1 failed to further increase serum P$_i$ levels, or to curb the increase in P$_i$ excretion that takes place during hypomagnesemia (Fig. 3C). Thus, EGFR is involved in the regulation of P$_i$ excretion during normal conditions, but plays no additional role in regulating P$_i$ during Mg$^{2+}$ deprivation. As expected, Mg$^{2+}$ deprivation decreased Na$^+$ excretion (Fig. 4A), but ME-1 had no effect in either Na$^+$ excretion or serum Na$^+$ (Fig. 4B). Furthermore, Mg$^{2+}$ deprivation reduced K$^+$ excretion and increased serum K$^+$ (Fig. 4D). ME-1 had no effect on K$^+$ excretion, but interestingly, it decreased serum K$^+$ during Mg$^{2+}$ deprivation.

**Discussion**

The present study investigated the effect of blocking EGFR with ME-1 for 2 weeks and found that mice

![](https://example.com/image1.png)

| Table 1. Serum and urine electrolyte composition of mice following a 2 week treatment with ME-1 or control rat IgG. |
|-------------------------------------------------|
| **Measurement** | **Control** | **ME-1** | **Normal range**$^1$ |
| Serum | | | |
| [Mg$^{2+}$] (mmol/L) | 1.12 ± 0.01 | 1.04 ± 0.03$^2$ | 1.1–1.4 |
| [Ca$^{2+}$] (mmol/L) | 2.11 ± 0.09 | 2.24 ± 0.07 | 2.0–2.8 |
| [P$_i$] (mmol/L) | 2.67 ± 0.01 | 2.96 ± 0.09$^2$ | 2.2–3.0 |
| [Na$^+$] (mmol/L) | 158.0 ± 2.9 | 155.0 ± 2.2 | 130–160 |
| [K$^+$] (mmol/L) | 4.90 ± 0.19 | 5.54 ± 0.25 | 4.5–7.5 |
| Urine | | | |
| Volume (mL/24 h) | 1.34 ± 0.12 | 1.31 ± 0.17 | n/a |
| Mg$^{2+}$ excretion (μmol/24 h) | 23.65 ± 2.50 | 18.52 ± 3.0 | n/a |
| Ca$^{2+}$ excretion (μmol/24 h) | 0.30 ± 0.03 | 0.30 ± 0.03 | n/a |
| P$_i$ excretion (μmol/24 h) | 91.1 ± 8.5 | 88.0 ± 6.6 | n/a |
| Na$^+$ excretion (μmol/24 h) | 191.7 ± 17.5 | 178.8 ± 22.6 | n/a |
| K$^+$ excretion (μmol/24 h) | 199.3 ± 12.5 | 202.7 ± 17.1 | n/a |

$^1$Normal serum values are based on the values provided by the Research Animal Resources at the University of Minnesota and on experiments performed in our lab.
$^2$Data compared by unpaired Student’s t-test; $P < 0.05$ compared to control group. Data represent mean ± SE; $n = 6–7$.
developed a moderate reduction in serum Mg²⁺, while no changes in Mg²⁺ excretion were detected. In contrast, serum Pi levels were clearly affected. Interestingly, a single dose of ME-1 was effective in reducing Pi excretion and triggering hyperphosphatemia. Moreover, blocking EGFR with ME-1 did not affect the acute Mg²⁺-conservation response triggered by dietary Mg²⁺ deprivation. Taken together, our research indicates that EGF might be more involved in regulating Pi than Mg²⁺ metabolism in mice.

Previous studies on the ability of the EGFR inhibitor erlotinib to induce hypomagnesemia in rodents showed no effect after 10 days of treatment, and only a moderate effect (10–14%) after 3 weeks of treatment (Dimke et al. 2010; Mak et al. 2015). Chemical inhibitors do not affect Mg²⁺ metabolism in human patients, so we decided to use the rat monoclonal EGFR inhibitor ME-1 to investigate its effects on Mg²⁺ balance in mice. Due to the possibility of mice developing an adaptive immune response to this rat monoclonal antibody, our study was limited to 2 weeks. Despite a significant effect of ME-1 on the mice integument (Fig. 1), blocking EGFR with ME-1 for 2 weeks resulted in a modest 7.1% decrease in serum Mg²⁺ (Table 1, P < 0.05) versus control diet with control rat IgG (*) or control diet with ME-1 (#). ANOVA followed by Fisher’s LSD test.

Figure 3. EGFR inhibition during short-term Mg²⁺-deprivation affects metabolism of Pi, but not that of Ca²⁺. (A) Ca²⁺ excretion was affected by Mg²⁺ deprivation, but not by EGFR inhibition. (B) Development of hypocalcemia due to Mg²⁺ restriction was not affected by ME-1 administration. (C) ME-1 administration resulted in decreased Pi excretion in mice fed control diet. Dietary Mg²⁺ deprivation is characterized by a sharp increase in Pi excretion. Under these conditions, EGFR inhibition with ME-1 was unable to decrease Pi excretion. (D) ME-1 induced decreased Pi excretion resulted in hyperphosphatemia, similar to the effect of Mg²⁺-deprivation. Data represent mean ± SE; n = 6–7; P < 0.05 versus control diet with control rat IgG (*) or control diet with ME-1 (#). ANOVA followed by Fisher’s LSD test.
deprivation, Mg$^{2+}$ excretion was still reduced and hypocalciuria and hyperphosphaturia persisted, but serum levels of K$, Ca^{2+}$, and Pi have been normalized (Ortega et al. 2015). Thus, Mg$^{2+}$ restriction elicits a quick adaptation response involving many electrolytes. In the present study, we investigated if EGF played any role in the Mg$^{2+}$ conservation response that characterizes short-term hypomagnesemia. As shown in Figure 2, blocking EGFR with ME-1 did not affect serum Mg$^{2+}$ or Mg$^{2+}$ excretion in Mg$^{2+}$ deprived mice. Other electrolytes, like Ca$^{2+}$, Pi (Fig. 3) or Na$^{+}$ (Fig. 4), responded to changes in the Mg$^{2+}$ composition of the diet, but were unaffected by treatment with ME-1. Interestingly, ME-1 was able to prevent the increase in serum K$^+$ triggered by Mg$^{2+}$ deprivation, although we ignore the mechanism of this effect. Thus, EGF appears to play a minimal role in regulating Mg$^{2+}$ conservation at the nephron, although, extended exposure to EGFR-targeting medications does ultimately compromise the ability of nephrons to preserve Mg$^{2+}$, as shown by others (Schrag et al. 2005; Dimke et al. 2010; Mak et al. 2015).

Interestingly, 2 weeks of repeated injection with ME-1 resulted in a significant increase in serum Pi (table 1). To our knowledge, this is the first observation that blocking EGFR increases serum Pi in mice. A common cause of hyperphosphatemia is a decline in renal function. However, our study did not show a rise in serum K$^+$ or a decline in serum Ca$^{2+}$ that would suggest compromised kidney function. Previous studies in rats have shown that administration of EGF reduces expression of the Na$^+/P_i$ cotransporter NaPi-2 in proximal convoluted tubule (PCT), potentially increasing P$_i$ excretion (Arar et al. 1999). In our study, the ability of EGF to rapidly affect electrolyte transport in the nephron is demonstrated by the effect of a single dose of ME-1 on P$_i$ metabolism in mice. Two days after animals on a control diet were injected with one dose of ME-1, P$_i$ excretion was reduced by 45% (Fig. 3C) and serum P$_i$ increased by 20%.

Figure 4. Effect of ME-1 administration on Na$^+$ and K$^+$ balance. (A) Na$^+$ excretion was reduced by Mg$^{2+}$ deprivation, but not by EGFR inhibition. (B) Mg$^{2+}$ deprivation increased serum Na$^+$. (C) K$^+$ excretion was reduced in Mg$^{2+}$-deprived mice. ME-1 did not significantly affect K$^+$ excretion in either group. (D) Serum K$^+$ was increased in Mg$^{2+}$-deprived mice, but this effect was prevented by ME-1 inhibition of EGFR. Data represent mean ± SE; n = 6–7; P < 0.05 versus group with control diet and control rat IgG (*), control diet with ME-1 (#) or Mg$^{2+}$-deficient diet with ME-1 (+). ANOVA followed by Fisher’s LSD test.
resulting in hyperphosphatemia. Thus, both long-term or short-term administration of ME-1 affects P_i metabolism. These results are in line with previous studies in rats showing that treating animals with EGF for 48 h is enough to decrease NaPi-2 protein abundance (Arar et al. 1999). In our system, hyperphosphatemia likely results from reduction in P_i excretion due to increased P_i reabsorption at the PCT. This change is mediated by an increase in the number of NaPi-2 cotransporters at the plasma membrane of PCT cells due to decreased EGF stimulation. A limitation of this study is that we did not analyze the effect of ME-1 in the small intestine. In fact, hyperphosphatemia could result from increased intestinal P_i reabsorption, but in that case P_i excretion would probably be elevated.

A hypothesis for the mechanism translating EGFR inhibition into reduced NaPi-2 expression at the PCT is provided by the recent observation that EGF increases transcription of Klotho (KL) in HEK293 cells (Choi et al. 2010). KL acts as an obligate co-receptor of the FGF23 receptor FGFR1 that mediates inhibition of NaPi-2 expression in PCT cells via a mechanism involving phosphorylation of Na^+/H^+ exchange regulatory cofactor (NHERF)-1 (Erben and Andrukhova 2016). ME-1-mediated inhibition of EGFR may decrease KL expression in PCT, preventing FGF23-mediated downregulation of NaPi-2 expression, thus decreasing phosphaturia. In contrast, during hypomagnesemia, increased P_i excretion may result from a reduction of NaP_i cotransporters induced by high serum P_i (Biber et al. 1988; Markovich et al. 1995), hypoparathyroidism (Rude et al. 1978) or increased serum FGF23 (Segawa et al. 2003; van Angelen et al. 2013; Matsuzaki et al. 2013). Indeed, PTH can induce phosphorylation of NHERF-1 and downregulation of NaPi-2 without involvement of FGF23 or FGFR1/KL (Erben and Andrukhova 2016). However, during hypomagnesemia PTH secretion is reduced due to parathyroid gland failure (Hermans et al. 1996; Thumfart et al. 2008; Rude et al. 2009). Given that ME-1 did not reduce P_i excretion in Mg^{2+}-deprived mice (Fig. 3C), the phosphaturia induced by Mg^{2+}-restriction is likely independent of both FGF23 and PTH, and might be better explained by the observed elevation in serum P_i (Fig. 3D).

In summary, our study shows that inhibition of EGFR with a single dose of ME-1 had no effects on Mg^{2+} balance. Furthermore, sustained ME-1 administration resulted in a modest effect on serum Mg^{2+} without visibly affecting Mg^{2+} excretion. In contrast, ME-1 had a profound effect on P_i metabolism that became apparent from the first dose of ME-1. Thus, in mice, EGFR appears to be more involved in the regulation of P_i balance than in Mg^{2+} metabolism.

Conflict of Interest

None declared.

References

Altundag, K., O. Altundag, M. Z. Baptista, S. Turen, and M. A. Atik. 2005. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl Cancer Inst. 97:1791–1792.
van Angelen, A. A., P. San-Cristobal, W. P. Pulszems, J. G. Hoenderop, and R. J. Bindels. 2013. The impact of dietary magnesium restriction on magnesirotropic and calciotropic genes. Nephrol. Dial. Transplant. 28:2983–2993.
Arar, M., H. K. Zajicek, I. Elshihabi, and M. Levi. 1999. Epidermal growth factor inhibits Na-P_i cotransport in weaned and suckling rats. Am. J. Physiol. 276:F72–F78.
Biber, J., J. Forgo, and H. Murer. 1988. Modulation of Na^-P_i cotransport in opossum kidney cells by extracellular phosphate. Am J Physiol - Cell Physiol 255:C155–C161.
Choi, B. H., C. G. Kim, Y. Lim, Y. H. Lee, and S. Y. Shin. 2010. Transcriptional activation of the human Klotho gene by epidermal growth factor in HEK293 cells; role of Egr-1. Gene 450:121–127.
Dimke, H., J. van der Wijst, T. R. Alexander, I. M. J. Meijer, G. M. Mulder, H. van Goor, et al. 2010. Effects of the EGFR inhibitor erlotinib on magnesium handling. J. Am. Soc. Nephrol. 21:1309–1316.
Erben, R. G., and O. Andrukhova. 2016. FGF23-Klotho signaling axis in the kidney. Bone, (in press). doi:10.1016/j.bone.2016.09.010.
Ferre, S., J. J. Hoenderop, and R. J. Bindels. 2011. Role of the distal convoluted tubule in renal Mg^2+ handling: molecular lessons from inherited hypomagnesemia. Magnes. Res. 24:S101–S108.
Fossati, P., M. Ponti, L. Principe, and G. Tarenghi. 1989. One-step protocol for assays of total and direct bilirubin with stable combined reagents. Clin. Chem. 35:173–176.
Goodyer, P. R., Z. Kachra, C. Bell, and R. Rozen. 1988. Renal tubular cells are potential targets for epidermal growth factor. Am. J. Physiol. 255:F1191–F1196.
Groenestege, W. M., S. Thebault, J. van der Wijst, D. van den Berg, R. Janssen, S. Teipar, et al. 2007. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J. Clin. Invest. 117:2260–2267.
Hermans, C., C. Lefebvre, J. P. Devogelaer, and M. Lambert. 1996. Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Clin. Rheumatol. 15:193–196.
Izzedine, H., R. Bahlada, D. Khayat, C. Massard, N. Magné, J. P. Spano, et al. 2010. Electrolyte disorders related to EGFR-targeting drugs. Crit. Rev. Oncol. Hematol. 73:213–219.
Kubitz, R., G. Südfels, T. Kühlkamp, R. Kölling, and D. Häussinger. 2004. Trafficking of the bile salt export pump...
from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 126:541–553.

Loriot, Y., G. Perlemuter, D. Malka, F. Penault-Lorca, V. Boige, E. Deutsch, et al. 2008. Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat. Clin. Pract. Oncol. 5:268–278.

MacManus, J., and F. W. Heaton. 1969. The effect of magnesium deficiency on calcium homeostasis in the rat. Clin. Sci. 36:297–306.

MacManus, J., and F. W. Heaton. 1969. The effect of magnesium deficiency on calcium homeostasis in the rat. Clin. Sci. 36:297–306.

Mak, I. T., J. H. Kramer, J. J. Chmielinska, C. F. Spurney, and W. B. Weglicki. 2015. EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J. Cardiovasc. Pharmacol. 65:54–61.

Markovich, D., T. Verri, V. Sorríbas, J. Forgo, J. Biber, and H. Murer. 1995. Regulation of opossum kidney (OK) cell Na/Pi cotransport by Pi deprivation involves mRNA stability. Pflüg. Arch. 430:459–463.

Matsuzaki, H., Y. Kajita, and M. Miwa. 2013. Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats. Magnes. Res. 26:18–23.

Ortega, B., J. R. MacWilliams, J. M. Dey, and V. B. Courtright. 2015. Hyperphosphatemia, hypocalcemia and increased serum potassium concentration as distinctive features of early hypomagnesemia in magnesium-deprived mice. Magnes. Res. 28:126–135.

Quigley, R., D. A. Kennerly, J. N. Sheu, and M. Baum. 1995. Stimulation of proximal convoluted tubule phosphate transport by epidermal growth factor: signal transduction. Am. J. Physiol. 269:F339–F344.

Rude, R. K., S. B. Oldham, C. F. Sharp, and F. R. Singer. 1978. Parathyroid hormone secretion in magnesium deficiency. J. Clin. Endocrinol. Metab. 47:800–806.

Rude, R. K., H. E. Gruber, L. Y. Wei, A. Frausto, and B. G. Mills. 2003. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. Calcif. Tissue Int. 72:32–41.

Rude, R. K., F. R. Singer, and H. E. Gruber. 2009. Skeletal and hormonal effects of magnesium deficiency. J. Am. Coll. Nutr. 28:131–141.

Schrag, D., K. Y. Chung, C. Flombaum, and L. Saltz. 2005. Cetuximab Therapy and Symptomatic Hypomagnesemia. J. Natl Cancer Inst. 97:1221–1224.

Segawa, H., E. Kawakami, I. Kaneko, M. Kuwahata, M. Ito, K. Kusano, et al. 2003. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflüg Arch Eur J Physiol 446:585–592.

Shafik, I. M., and G. A. Quamme. 1989. Early adaptation of renal magnesium reabsorption in response to magnesium restriction. Am. J. Physiol. 257:F974–F977.

Suruguladze, D., D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, et al. 2009. Tumor necrosis factor- and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 69:5643–5647.

Thumfart, J., S. Jung, S. Amasheh, S. Krämer, H. Peters, K. Sommer, et al. 2008. Magnesium stimulates renal phosphate reabsorption. Am. J. Physiol. Renal. Physiol. 295:F1126–F1133.